Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34.

Pyriochou A, Olah G, Deitch EA, Szabó C, Papapetropoulos A.

Int J Mol Med. 2008 Jul;22(1):113-8.

PMID:
18575783
2.

Reciprocal binding of PARP-1 and histone H1 at promoters specifies transcriptional outcomes.

Krishnakumar R, Gamble MJ, Frizzell KM, Berrocal JG, Kininis M, Kraus WL.

Science. 2008 Feb 8;319(5864):819-21. doi: 10.1126/science.1149250.

3.

PARPs database: a LIMS systems for protein-protein interaction data mining or laboratory information management system.

Droit A, Hunter JM, Rouleau M, Ethier C, Picard-Cloutier A, Bourgais D, Poirier GG.

BMC Bioinformatics. 2007 Dec 19;8:483.

4.

Plasma levels of nitric oxide and stroke outcome.

Taffi R, Nanetti L, Mazzanti L, Bartolini M, Vignini A, Raffaelli F, Pasqualetti P, Vernieri F, Provinciali L, Silvestrini M.

J Neurol. 2008 Jan;255(1):94-8.

PMID:
18080850
5.

Targeted cancer therapies based on the inhibition of DNA strand break repair.

O'Connor MJ, Martin NM, Smith GC.

Oncogene. 2007 Dec 10;26(56):7816-24. Review.

PMID:
18066095
6.

Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.

Lewis C, Low JA.

Curr Opin Investig Drugs. 2007 Dec;8(12):1051-6. Review.

PMID:
18058575
7.

PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites.

Haince JF, McDonald D, Rodrigue A, Déry U, Masson JY, Hendzel MJ, Poirier GG.

J Biol Chem. 2008 Jan 11;283(2):1197-208.

8.

Evaluation of the peroxynitrite decomposition catalyst Fe(III) tetra-mesitylporphyrin octasulfonate on peripheral neuropathy in a mouse model of type 1 diabetes.

Drel VR, Pacher P, Vareniuk I, Pavlov IA, Ilnytska O, Lyzogubov VV, Bell SR, Groves JT, Obrosova IG.

Int J Mol Med. 2007 Dec;20(6):783-92.

9.
10.

Metabolic profiling of arginine and nitric oxide pathways predicts hemodynamic abnormalities and mortality in patients with cardiogenic shock after acute myocardial infarction.

Nicholls SJ, Wang Z, Koeth R, Levison B, DelFraino B, Dzavik V, Griffith OW, Hathaway D, Panza JA, Nissen SE, Hochman JS, Hazen SL.

Circulation. 2007 Nov 13;116(20):2315-24.

11.

PARP-1 activation in the ERK signaling pathway.

Cohen-Armon M.

Trends Pharmacol Sci. 2007 Nov;28(11):556-60. Review.

PMID:
17950909
12.
13.

PARP inhibitor development for systemic cancer targeting.

Zaremba T, Curtin NJ.

Anticancer Agents Med Chem. 2007 Sep;7(5):515-23. Review.

PMID:
17896912
14.

Poly(ADP-ribose) polymerase expression in kidney transplantation: from alfa (alpha) to Omega (Omega).

O'Valle F, Gómez-Morales M, Del Moral RM, Serón D, Moreso F, Osuna A, Oliver FJ, Del Moral RG.

Transplant Proc. 2007 Sep;39(7):2099-101.

PMID:
17889105
15.

PARP-1-induced cell death through inhibition of the MEK/ERK pathway in MNNG-treated HeLa cells.

Ethier C, Labelle Y, Poirier GG.

Apoptosis. 2007 Nov;12(11):2037-49.

PMID:
17828454
16.

The DNA binding and catalytic domains of poly(ADP-ribose) polymerase 1 cooperate in the regulation of chromatin structure and transcription.

Wacker DA, Ruhl DD, Balagamwala EH, Hope KM, Zhang T, Kraus WL.

Mol Cell Biol. 2007 Nov;27(21):7475-85.

17.

Could serum antibody to poly(ADP-ribose) and/or histone H1 be marker for senile dementia of Alzheimer type?

Kanai Y, Akatsu H, Iizuka H, Morimoto C.

Ann N Y Acad Sci. 2007 Aug;1109:338-44.

PMID:
17785323
18.

Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis.

Tentori L, Lacal PM, Muzi A, Dorio AS, Leonetti C, Scarsella M, Ruffini F, Xu W, Min W, Stoppacciaro A, Colarossi C, Wang ZQ, Zhang J, Graziani G.

Eur J Cancer. 2007 Sep;43(14):2124-33.

PMID:
17714938
20.

Peroxynitrite: biochemistry, pathophysiology and development of therapeutics.

Szabó C, Ischiropoulos H, Radi R.

Nat Rev Drug Discov. 2007 Aug;6(8):662-80. Review.

PMID:
17667957
Items per page

Supplemental Content

Support Center